Loading
Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer.
Brian Rini was principal investigator of KEYNOTE-426, the trial showing pembrolizumab plus axitinib improves survival over sunitinib in first-line advanced renal cell carcinoma, and of IMmotion151 (atezolizumab plus bevacizumab). He has led studies of active surveillance in metastatic RCC and of biomarkers of immunotherapy response. He directs clinical trials at Vanderbilt-Ingram.
Shares VEGF / VEGFR, Renal cell carcinoma, PD-1, Pembrolizumab and the tags rcc, trialist.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares PD-1, Immune checkpoint inhibitors and the tags immunotherapy, trialist.
Shares VEGF / VEGFR, PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Renal cell carcinoma and the tags immunotherapy, trialist.